(Q34511480)

2 August 2017

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. (English)

1 reference

2 August 2017

0 references

2

1 reference

2 August 2017

T Safra

1

1 reference

2 August 2017

S Jeffers

3

1 reference

2 August 2017

D D Tsao-Wei

4

1 reference

2 August 2017

S Groshen

5

1 reference

2 August 2017

O Lyass

6

1 reference

2 August 2017

R Henderson

7

1 reference

2 August 2017

G Berry

8

1 reference

2 August 2017

A Gabizon

9

1 reference

2 August 2017

1 August 2000

1 reference

2 August 2017

1 reference

2 August 2017

11

1 reference

2 August 2017

8

1 reference

2 August 2017

1029-1033

1 reference

Risk factors for doxorubicin-induced congestive heart failure

2 August 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

Doxil in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008365716693

7 January 2021

Identifiers

DOI

10.1023/A:1008365716693

1 reference

2 August 2017

1 reference